We are live on ! Find out more
IBO

Impact BioMedical
IBO

19 hedge funds and large institutions have $305K invested in Impact BioMedical in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

19% more funds holding

Funds holding: 16 → 19 (+3)

1.01% more ownership

Funds ownership: 2.89% → 3.9% (+1%)

0% more capital invested

Capital invested by funds: $304K → $305K (+$836)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
19
Holders Change
+3
Holders Change %
+18.75%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$125K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$17.3K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$15K
4
UBS Group
UBS Group
Switzerland
+$13.2K
5
Two Sigma Investments
Two Sigma Investments
New York
+$12.7K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$52.7K
2
Citadel Advisors
Citadel Advisors
Florida
-$52.5K
3
HF
HRT Financial
New York
-$32.4K
4
Morgan Stanley
Morgan Stanley
New York
-$6.79K
5
TRCT
Tower Research Capital (TRC)
New York
-$1.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$164K +$125K +222,055 +724%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$32.3K +$15K +26,669 +115%
UBS Group
3
UBS Group
Switzerland
$25.7K +$13.2K +23,558 +146%
Vanguard Group
4
Vanguard Group
Pennsylvania
$21K -$52.7K -94,009 -74%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$19.9K +$17.3K +30,824 New
Two Sigma Investments
6
Two Sigma Investments
New York
$14.7K +$12.7K +22,700 New
State Street
7
State Street
Massachusetts
$7.63K – – –
SG
8
StoneX Group
New York
$6.99K +$6.05K +10,794 New
HF
9
HRT Financial
New York
$6K -$32.4K -57,832 -85%
Citigroup
10
Citigroup
New York
$5.68K +$4.93K +8,784 New
TRCT
11
Tower Research Capital (TRC)
New York
$938 -$1.3K -2,317 -62%
NFSG
12
Newbridge Financial Services Group
Florida
$56 – – –
Bank of America
13
Bank of America
North Carolina
$52 +$35 +63 +371%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$23 +$20 +36 New
Wells Fargo
15
Wells Fargo
California
$19 -$561 -1,000 -97%
SRCM
16
Signature Resources Capital Management
California
$3 – – –
DB
17
Danske Bank
Denmark
$2 – – –
Group One Trading
18
Group One Trading
Illinois
$1 – – –
Citadel Advisors
19
Citadel Advisors
Florida
– -$52.5K -60,315 Closed
Morgan Stanley
20
Morgan Stanley
New York
– -$6.79K -7,800 Closed

IBO Hedge Fund Activity: Q2 2025 in Review

19 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q2 2025, worth a combined $305K — up 0.28% from $304K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IBO positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $125K. The largest seller was Vanguard Group, cutting an estimated $52.7K.

  • 19 institutional investors held Impact BioMedical (IBO) as of Q2 2025, up from 16 in Q1 2025.
  • Funds reported $305K of Impact BioMedical stock for Q2 2025, up 0.28% quarter-over-quarter.
  • 5 funds opened new Impact BioMedical positions in Q2 2025 and 2 closed out, a net change of +3 holders.
  • The largest Impact BioMedical buyer in Q2 2025 was BlackRock, an estimated $125K added.
  • The largest Impact BioMedical seller in Q2 2025 was Vanguard Group, an estimated $52.7K sold.

Based on aggregated 13F filings for Q2 2025.